Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Abstract T-LAK cell-oriented protein kinase (TOPK) is a potential therapeutic target in tumors. However, its role in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) has not been reported. Here, we found that TOPK was highly expressed in ALK-positive NSCLC. Additionally,...
Main Authors: | Juanjuan Xiao, Lu Zhang, Huijun Yi, Ling Zou, Jianmei Mo, Feng Xue, Jinhua Zheng, Yingze Huang, Hui Lu, Hansheng Wu, Peipei Xue, Xin Zhang, Lifei He, Zhaoxin Li, Shigui Pang, Guibin Qiao, Qiuhong Duan, Feng Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-09-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-022-05260-3 |
Similar Items
-
ALK Inhibitors in the Treatment of ALK Positive NSCLC
by: Muhammad Khan, et al.
Published: (2019-01-01) -
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
by: Qian Zhu, et al.
Published: (2017-06-01) -
Current status and challenges of immunotherapy in ALK rearranged NSCLC
by: Rongbin Qi, et al.
Published: (2022-12-01) -
First-Line Treatment of _ALK_-Positive NSCLC
by: Hasna Bouchaab
Published: (2020-11-01) -
Therapeutic Sequencing in ALK<sup>+</sup> NSCLC
by: Mei Elsayed, et al.
Published: (2021-01-01)